Skip to main content
. 2017 Mar 20;7:43792. doi: 10.1038/srep43792

Figure 3. Comparison the performance of our method with RLSMDA and NCPMDA for prioritizing the diseases associated with the specific microRNAs using leave-one-out cross-validation experiments.

Figure 3

(A) The ROC curve. (B) The PR curve.